Cancers are a group of heterogeneous diseases characterized by the acquisition of
functional capabilities during the transition from a normal to a neoplastic state. Powerful …

With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …

Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical
challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined …

Summary Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective
for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced …

Summary Exhausted CD8 T (T ex) cells in chronic viral infection and cancer have sustained
co-expression of inhibitory receptors (IRs). T ex cells can be reinvigorated by blocking IRs …

Immunological control of residual leukemia cells is thought to occur in patients with chronic
myeloid leukemia (CML) that maintain treatment-free remission (TFR) following tyrosine …

The differentiation, survival, and effector function of tumor-specific CD8+ cytotoxic T cells lie
at the center of antitumor immunity. Due to the lack of proper costimulation and the abundant …

Immune checkpoint inhibitors have effectively transformed the treatment of many cancers,
particularly those highly devastating malignancies. With their widespread popularity, the …

Advances in melanoma research have unveiled critical insights into its genetic and
molecular landscape, leading to significant therapeutic innovations. This review explores the …

Natural killer (NK) cells integrate heterogeneous signals for activation and inhibition using
germline-encoded receptors. These receptors are stochastically co-expressed, and their …